Twist Bioscience (NASDAQ:TWST – Get Free Report) had its price target dropped by stock analysts at Barclays from $215.00 to $130.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 16.07% from the stock’s current price.
Other equities analysts also recently issued research reports about the company. Jefferies Financial Group set a $125.00 price target on Twist Bioscience in a research report on Thursday, November 12th. Piper Sandler upped their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Leerink Partners decreased their price target on shares of Twist Bioscience from $190.00 to $175.00 and set an “outperform” rating on the stock in a report on Friday, November 13th. Finally, Guggenheim boosted their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $133.92.
Check Out Our Latest Research Report on TWST
Twist Bioscience Trading Up 6.6%
Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Twist Bioscience had a negative net margin of 28.34% and a negative return on equity of 27.53%. The firm had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. Twist Bioscience’s revenue was up 26.7% on a year-over-year basis. On average, equities research analysts expect that Twist Bioscience will post -1.52 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, insider Dennis Cho sold 949 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total value of $128,494.60. Following the completion of the sale, the insider owned 62,840 shares in the company, valued at approximately $8,508,536. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,462 shares of the stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $156.30, for a total transaction of $384,810.60. Following the completion of the sale, the chief financial officer directly owned 98,114 shares of the company’s stock, valued at $15,335,218.20. This trade represents a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 495,279 shares of company stock valued at $80,489,387. 3.08% of the stock is owned by insiders.
Institutional Trading of Twist Bioscience
A number of hedge funds and other institutional investors have recently made changes to their positions in TWST. BlackRock Inc. bought a new stake in shares of Twist Bioscience in the 2nd quarter worth about $600,191,000. William Blair Investment Management LLC acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth approximately $223,722,000. Goldman Sachs Group Inc. lifted its stake in Twist Bioscience by 21.7% in the third quarter. Goldman Sachs Group Inc. now owns 1,714,716 shares of the company’s stock valued at $331,352,000 after buying an additional 306,298 shares during the last quarter. Bank of America Corp DE bought a new stake in Twist Bioscience in the 2nd quarter valued at about $94,922,000. Finally, Stephens Investment Management Group LLC raised its holdings in shares of Twist Bioscience by 1.7% during the third quarter. Stephens Investment Management Group LLC now owns 780,419 shares of the company’s stock valued at $150,808,000 after buying an additional 13,055 shares during the last quarter.
Twist Bioscience Company Profile
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
Featured Articles
- Five stocks we like better than Twist Bioscience
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
